Cancer Research UK has become a member of the Workforce Development Steering Committee of the Association of Clinical Research Professionals (ACRP).
Cancer Research UK has become a member of the Workforce Development Steering Committee of the Association of Clinical Research Professionals (ACRP).
The group’s main goal is to review and approve core competence standards for clinical research professionals. Its members comprise industry and academic organizations across the global clinical research sector.
"Cancer Research UK has long supported the training and development of the next generation of clinical research professionals," says Dr. Nigel Blackburn, Cancer Research UK's director of drug development. "We're really pleased that we now have the opportunity to contribute to this international collaboration led by ACRP which will help to maintain a high quality in clinical research across the globe."
As its first initiative, the committee will request public comment on a competence framework for clinical research associates (CRAs). This framework will define standards for clinical trial monitors/CRAs within the eight core competence domains for clinical research professionals, as defined by the Joint Task Force for Clinical Trial Competence.
"ACRP is excited to announce Cancer Research UK as a member of the ACRP Workforce Development Steering Committee," says Terri Hinkley, RN, BScN, MBA, CCRC, FACRP, ACRP's Workforce Innovation Officer. "We are thankful for Cancer Research UK's willingness to support workforce competence standardization as a means of promoting excellence in clinical research.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.